| Title |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
|
|---|---|
| Published in |
Vascular Health and Risk Management, November 2013
|
| DOI | 10.2147/vhrm.s49840 |
| Pubmed ID | |
| Authors |
JoAnne M Foody, Peter P Toth, Joanne E Tomassini, Shiva Sajjan, Dena R Ramey, David Neff, Andrew M Tershakovec, Henry Hu, Kaan Tunceli |
| Abstract |
Many high-risk coronary heart disease (CHD) patients on statin monotherapy do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals, and combination lipid-lowering therapy may be considered for these individuals. The effect of adding ezetimibe to simvastatin, atorvastatin, or rosuvastatin therapy versus titrating these statins on LDL-C changes and goal attainment in CHD or CHD risk-equivalent patients was assessed in a large, managed-care database in the US. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 7 | 15% |
| Researcher | 7 | 15% |
| Student > Bachelor | 6 | 13% |
| Student > Master | 6 | 13% |
| Other | 2 | 4% |
| Other | 5 | 11% |
| Unknown | 14 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 5 | 11% |
| Unknown | 18 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2022.
All research outputs
#7,355,930
of 25,373,627 outputs
Outputs from Vascular Health and Risk Management
#243
of 804 outputs
Outputs of similar age
#64,074
of 226,646 outputs
Outputs of similar age from Vascular Health and Risk Management
#7
of 18 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,646 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.